News Summit shrugs off survival miss with its VEGF bispecific Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.
News Astellas adds to claudin clout with $1.3bn+ Evopoint deal Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.
News Roche builds case for MS drug with two-year efficacy data Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.
News GRIN raises $140m for epilepsy drug, and other financings Our round-up of recent biotech financings includes rounds for GRIN Therapeutics, GlycoEra, Syndeio, Juvenescence, and Vima Therapeutics.
News MSD and Daiichi Sankyo pull HER3-DXd's FDA filing MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.
News Moderna's $760m-plus flu vaccine contracts are nixed by HHS HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack on mRNA technology.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
